This preview shows pages 1–2. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: I believe the former. By submitting a counter offer for DeKalb, Novartis will position itself as a dominant player and if the offer is accepted, will have positioned itself in line with its purpose of life-sciences. Not to mention, Novartis will also have the advantage in corn genetics which in today’s world is showing to be very profitable indeed. Moreover, further innovation in corn genetics would be applicable in one for or another across Novartis’ other business operations. The only downfall of this option would be the unexpected cost that come with such an offer; however, due to the ability for this endeavor to effect all business operations, monies can be sourced from other departments as well other than simply agriculture. All in all Novartis will prevail if they employ this strategy....
View Full Document
This essay was uploaded on 02/20/2009 for the course AEM 4420 taught by Professor Christy,r. during the Fall '06 term at Cornell.
- Fall '06